Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for skin diseases requiring medical intervention. Co.'s product pipeline consists of: VP-102, which is a propriety drug-device combination that contains a good manufacturing practices-controlled formulation of cantharidin which is being developed for potential use in treating molluscum contagiosum, external genital warts and common warts; VP-315, which is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma; and VP-103, which is a cantharidin based drug device combination for the potential treatment of plantar warts. The VRCA stock yearly return is shown above.
The yearly return on the VRCA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VRCA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|